FDA Grants Accelerated Approval to Encorafenib with Cetuximab and mFOLFOX6 for Patients with BRAF V600E-mutated mCRC
Evidence for efficacy is based on the results from the BREAKWATER study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1581 results
EMA Recommends Extension of Indications for Dostarlimab
Change concerns the first-line treatment of patients with endometrial cancer
Trastuzumab Emtansine Improves OS with Sustained Improvement in iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment
Findings from the KATHERINE study
Manageable Safety and Promising Activity of Neoadjuvant Pembrolizumab plus Vibostolimab, Pembrolizumab plus Gebasaxturev and Pembrolizumab Monotherapy in Stage IIIB–D Melanoma
Findings from a substudy 02C of the KEYMAKER-U02 trial
Dual Antigen Targeting with Talquetamab plus Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma
Findings from the RedirecTT-1 study
FDA Approves Durvalumab for Limited-Stage Small Cell Lung Cancer
Evidence for efficacy is based on the results from the ADRIATIC study
EMA Recommends Granting a Conditional Marketing Authorisation for Belzutifan
It is intended for the treatment of patients with advanced clear cell renal cell carcinoma and von Hippel-Lindau disease-associated tumours
Immune Checkpoint Inhibitor-Based Systemic Therapy Combinations for Patients with HCC Amenable to TACE
Findings from the EMERALD-1 and LEAP-012 studies
Omission of Surgical Axillary Staging Noninferior To Sentinel Lymph Node Biopsy in Patients with cN0, T1 or T2 Invasive Breast Cancer
Findings from the INSEMA study
Adding Blinatumomab to Chemotherapy Improves DFS in Patients with Newly Diagnosed Childhood Standard-Risk B-Cell ALL of Average or High Risk of Relapse
Findings from the COG AALL1731 study
FDA Grants Accelerated Approval to Zenocutuzumab-zbco for Non-Small Cell Lung Cancer and Pancreatic Adenocarcinoma
Evidence for efficacy is based on the results from the eNRGy study
EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab
New indication concerns a combination of nivolumab and ipilimumab for first-line treatment of patients with dMMR/MSI-H unresectable or metastatic colorectal cancer